Retatrutide has progressed into Phase 3 programs targeting obesity (with and without diabetes), focusing on durability of weight loss, cardiometabolic outcomes, and broader population validation
prices starting at $149$299/month for eligible medications Manufacturer patient assistance programs Novo Nordisk and Eli Lilly both offer savings programs for qualifying low-income patients
Who qualifies, and what results look like, are individual, and we settle that at the consultation
Reserve your consultation today and start erecting the health foundation your future deserves
Understanding an individual's genetic architecture in these pathways may support more informed medication selection and dose titration, though genetic predisposition does not determine exact treatment outcomes
Check your specific plans benefits and search for Zepbound in the drug formulary to determine the required coverage